phive2015
Roth MKM recently began coverage of Accuray (NASDAQ:ARAY) with a buy rating, highlighting the company’s penetration into emerging markets like China and India.
According to Roth, Accuray has secured approximately 10% of the radiation oncology market and is now consistently generating cash.
The analysts in a note stated, “Expansion into the value-priced segment with Tomo C, first installations in June FY Q4 2024, in China and Helix in India in FY 2025 positions Accuray to compete more effectively in faster-growing emerging markets.”
They added, “This expansion should boost revenue growth from low-mid-single digits to at least mid-high-single digits, warranting investor attention and higher valuation.”
Roth has set the price target for the stock at $9.
